Replies to post #64960 on US Stem Cell Inc (USRM)

[0mn1]

It never hit 80$ it had reverse splits which changed the chart

[pennystocKING13]

I would consider giving my left one for extended life. But i would rather go the easy route and just give up some of my fat and have scientists isolate my stem cells and dose me where i need it and have it fix my joint problems. Go USRM!

[NoMoDo]

It didn't hit $80. Instead, they reverse split and the current value compared to the historic value is as if the stock was at $80.

The company was almost bankrupt. It was managed by a bunch of scientists and one business guy, but they got into big time debt not being able to fund their phase 3 trial. Much of the debate over stem cells hurt USRM even though the debate was over embrionic stem cells. USRM works with adult stem cells because they are more stable in their growth. Further, due to the process of FDA licensing application (BLA), regenerative medicine (ie. stem cell therapy) was almost impossible to gain approval. That is until the introduction of RMAT designation to counteract our falling behind the rest of the world in this type of therapy.

Back in February, bets were being taken as to whether the company would end up in receivership. They were being sued by the largest financial backer for non-payment (Northsar). Their products were good, but they just couldn't handle the debt - especially since they already financed with toxic debt and it made the shares pretty much worthless.

According to PACER (court reporting system), there were a couple offers to buy USRM on the table, but those offers were rejected. Partially because Northstar realized the real value of the company.

Northstar worked out a deal with USRM where they would received a % of USRM, put their CEO on the USRM board, and clean up the company to make it a viable business or make it more attractive to buyers.

USRM cleaned up its balance sheet and income statement. It eliminated the toxic debt, paid off loans, found a bushiness partner to open 10 clinics and give the company needed capitol to work with the FDA and generate sales. Meanwhile, they applied for RMAT designation that could potentially allow them fast track to finish their phase 3 trials or even gain phase 4 approval that would allow them to immediately begin marketing a successful treatment for chronic heart failure.

Without Myocell FDA approval in the US, the company will still do just fine. Their core business does not require FDA approval because patients have their own stem cells removed and re-inerted. They are also using Myocell therapy in other countries that do not require federal approval. If however, they gain approval, they will for the time being, be the lone therapy worldwide, that regrows the heart for the number one cause of death in the world.